$3.4 Bn Liquid Biopsy Market to 2024 - Global Analysis by Cancer, Product, Circulating Biomarkers, Clinical Application, Regions, and Companies - ResearchAndMarkets.com
Aug. 23, 2018
DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The "Liquid Biopsy Market, Global Analysis by Cancer, Product, Circulating Biomarkers, Clinical Application, Regions, and Companies" report has been added to ResearchAndMarkets.com's offering.
Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world.
Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.
Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.
The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient's tumor and provide clues about the treatment that a patient's needs.
All the 9 Companies Studied in the Report have been Studied from 3 PointsCompany Overview Product Portfolio Financial Insight
This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.
By CancerLung Cancer Breast Cancer Colorectal Cancer Prostate Cancer Others
By ProductKits & Consumables Instruments Services
By Circulating BiomarkersCirculating Tumor Cells (CTCs) Circulating Tumor DNA (ctDNA) Exosomes
By SamplePlasma/Serum Urine Others
By Clinical ApplicationMonitoring Prognosis Theranostics Screening
By CompaniesThermo Fisher Scientific Inc. Roche Diagnostics Bio-Rad Laboratories Inc. Biocept Inc. Biocartis Myriad Genetics, Inc. Genomic Health NeoGenomics Laboratories Qiagen
For more information about this report visit https://www.researchandmarkets.com/research/cdqhv3/3_4_bn_liquid?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005412/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/23/2018 08:56 AM/DISC: 08/23/2018 08:56 AM